Increased growth hormone response to sumatriptan challenge in adult autistic disorders

Sherie Novotny, Eric Hollander, Andrea Allen, Serge Mosovich, Bonnie Aronowitz, Charles Cartwright, Concetta Decaria, Rima Dolgoff-Kaspar

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Serotonergic (5-HT) abnormalities have been documented in autism. To assess sensitivity of the 5-HT1d receptor, growth hormone response to the 5-HT1d receptor agonist sumatriptan was studied in adult autistic patients and matched normal controls. In this study, 11 adult patients with autism or Asperger's disorder were compared with nine matched controls. All subjects were randomized to single dose sumatriptan (6 mg SQ) and placebo challenges, separated by a 1-week interval, and growth hormone was measured before and during the challenges. The results showed a highly significant diagnosisxdrugxtime interaction on repeated measure analysis covaried for baseline. This suggests that autistic patients had significantly greater growth hormone response to sumatriptan than normal controls, independent of placebo effects. Therefore, abnormalities in 5-HT regulation in autism may be related to increased sensitivity of the 5-HT1d inhibitory receptor in autism. Copyright (C) 2000 Elsevier Science Ireland Ltd.

Original languageEnglish (US)
Pages (from-to)173-177
Number of pages5
JournalPsychiatry Research
Volume94
Issue number2
DOIs
StatePublished - May 15 2000
Externally publishedYes

Fingerprint

Sumatriptan
Autistic Disorder
Growth Hormone
Serotonin
Asperger Syndrome
Somatotropin Receptors
Placebo Effect
Placebos

Keywords

  • Asperger's disorder
  • Autism
  • Growth hormone
  • Serotonin
  • Sumatriptan

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Psychology(all)

Cite this

Novotny, S., Hollander, E., Allen, A., Mosovich, S., Aronowitz, B., Cartwright, C., ... Dolgoff-Kaspar, R. (2000). Increased growth hormone response to sumatriptan challenge in adult autistic disorders. Psychiatry Research, 94(2), 173-177. https://doi.org/10.1016/S0165-1781(00)00134-7

Increased growth hormone response to sumatriptan challenge in adult autistic disorders. / Novotny, Sherie; Hollander, Eric; Allen, Andrea; Mosovich, Serge; Aronowitz, Bonnie; Cartwright, Charles; Decaria, Concetta; Dolgoff-Kaspar, Rima.

In: Psychiatry Research, Vol. 94, No. 2, 15.05.2000, p. 173-177.

Research output: Contribution to journalArticle

Novotny, S, Hollander, E, Allen, A, Mosovich, S, Aronowitz, B, Cartwright, C, Decaria, C & Dolgoff-Kaspar, R 2000, 'Increased growth hormone response to sumatriptan challenge in adult autistic disorders', Psychiatry Research, vol. 94, no. 2, pp. 173-177. https://doi.org/10.1016/S0165-1781(00)00134-7
Novotny, Sherie ; Hollander, Eric ; Allen, Andrea ; Mosovich, Serge ; Aronowitz, Bonnie ; Cartwright, Charles ; Decaria, Concetta ; Dolgoff-Kaspar, Rima. / Increased growth hormone response to sumatriptan challenge in adult autistic disorders. In: Psychiatry Research. 2000 ; Vol. 94, No. 2. pp. 173-177.
@article{3066e995f3cb4cf4b7bbdfe85aa90967,
title = "Increased growth hormone response to sumatriptan challenge in adult autistic disorders",
abstract = "Serotonergic (5-HT) abnormalities have been documented in autism. To assess sensitivity of the 5-HT1d receptor, growth hormone response to the 5-HT1d receptor agonist sumatriptan was studied in adult autistic patients and matched normal controls. In this study, 11 adult patients with autism or Asperger's disorder were compared with nine matched controls. All subjects were randomized to single dose sumatriptan (6 mg SQ) and placebo challenges, separated by a 1-week interval, and growth hormone was measured before and during the challenges. The results showed a highly significant diagnosisxdrugxtime interaction on repeated measure analysis covaried for baseline. This suggests that autistic patients had significantly greater growth hormone response to sumatriptan than normal controls, independent of placebo effects. Therefore, abnormalities in 5-HT regulation in autism may be related to increased sensitivity of the 5-HT1d inhibitory receptor in autism. Copyright (C) 2000 Elsevier Science Ireland Ltd.",
keywords = "Asperger's disorder, Autism, Growth hormone, Serotonin, Sumatriptan",
author = "Sherie Novotny and Eric Hollander and Andrea Allen and Serge Mosovich and Bonnie Aronowitz and Charles Cartwright and Concetta Decaria and Rima Dolgoff-Kaspar",
year = "2000",
month = "5",
day = "15",
doi = "10.1016/S0165-1781(00)00134-7",
language = "English (US)",
volume = "94",
pages = "173--177",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Increased growth hormone response to sumatriptan challenge in adult autistic disorders

AU - Novotny, Sherie

AU - Hollander, Eric

AU - Allen, Andrea

AU - Mosovich, Serge

AU - Aronowitz, Bonnie

AU - Cartwright, Charles

AU - Decaria, Concetta

AU - Dolgoff-Kaspar, Rima

PY - 2000/5/15

Y1 - 2000/5/15

N2 - Serotonergic (5-HT) abnormalities have been documented in autism. To assess sensitivity of the 5-HT1d receptor, growth hormone response to the 5-HT1d receptor agonist sumatriptan was studied in adult autistic patients and matched normal controls. In this study, 11 adult patients with autism or Asperger's disorder were compared with nine matched controls. All subjects were randomized to single dose sumatriptan (6 mg SQ) and placebo challenges, separated by a 1-week interval, and growth hormone was measured before and during the challenges. The results showed a highly significant diagnosisxdrugxtime interaction on repeated measure analysis covaried for baseline. This suggests that autistic patients had significantly greater growth hormone response to sumatriptan than normal controls, independent of placebo effects. Therefore, abnormalities in 5-HT regulation in autism may be related to increased sensitivity of the 5-HT1d inhibitory receptor in autism. Copyright (C) 2000 Elsevier Science Ireland Ltd.

AB - Serotonergic (5-HT) abnormalities have been documented in autism. To assess sensitivity of the 5-HT1d receptor, growth hormone response to the 5-HT1d receptor agonist sumatriptan was studied in adult autistic patients and matched normal controls. In this study, 11 adult patients with autism or Asperger's disorder were compared with nine matched controls. All subjects were randomized to single dose sumatriptan (6 mg SQ) and placebo challenges, separated by a 1-week interval, and growth hormone was measured before and during the challenges. The results showed a highly significant diagnosisxdrugxtime interaction on repeated measure analysis covaried for baseline. This suggests that autistic patients had significantly greater growth hormone response to sumatriptan than normal controls, independent of placebo effects. Therefore, abnormalities in 5-HT regulation in autism may be related to increased sensitivity of the 5-HT1d inhibitory receptor in autism. Copyright (C) 2000 Elsevier Science Ireland Ltd.

KW - Asperger's disorder

KW - Autism

KW - Growth hormone

KW - Serotonin

KW - Sumatriptan

UR - http://www.scopus.com/inward/record.url?scp=0034656974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034656974&partnerID=8YFLogxK

U2 - 10.1016/S0165-1781(00)00134-7

DO - 10.1016/S0165-1781(00)00134-7

M3 - Article

VL - 94

SP - 173

EP - 177

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 2

ER -